Health Canada concluded the vaccine has an efficacy rate of 66.9 per cent in preventing moderate to severe COVID-19 illness, and has authorized it for use for adults aged 18 and older.
OCTA chief clarifies AstraZeneca vaccine ‘low efficacy’ comment
The main purpose of vaccines is to keep people out of the hospital and lower their risk of dying. Even vaccines with lower efficacy against mild and moderate disease, such as Johnson & Johnson’s shot, show better efficacy against severe illness
Opinion: Despite the recent focus on certain efficacy rates without context, the Johnson & Johnson vaccine is not an inferior shot. It's no less worthy of your arm, and its authorization is a huge public health win for the US
The Johnson & Johnson vaccine shows a 72% efficacy rate in the U.S., falling way short of the rates in Moderna and Pfizer studies, which hover around 95%.
NEW—Interim analysis of Russian#COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19 . No serious adverse events were deemed to be associated with vaccination.
COVAXIN has demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR: Bharat Biotech
CDC caught in a lie — studies do not show efficacy of vaccine in previously infected COVID patients. Vaccines should be prioritized for people who have not yet had COVID. .
Breaking: Novavax Covid vaccine shows 89% efficacy in UK trials. Half the cases on the trial were the new ‘Kent’variant so this is first vaccine to show it is effective against the new more contagious variant